Insider buying last 90 days
No open-market insider purchases were filed for IRTC in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every IRTC insider filing, plotted on the chart in Gekko.Open IRTC in Gekko
NASDAQ: IRTC
iRhythm (IRTC) Stock Analysis & Forecast
Oct 12 close
$106.68−0.02 (0.0%)
Gekko Brief
AI summaryOct 12 closeThis week's news for iRhythm centers on a cybersecurity incident disclosed on 9 October, involving unauthorized access to patient data, which prompted a regulatory investigation and revised financial guidance; a related class action investigation by Edelson Lechtzin LLP has also surfaced. Alongside this, iRhythm completed its acquisition of VitalConnect, a cardiac monitoring technology company, for $287.5 million, broadening its platform beyond wearable heart patches, with commentary suggesting the deal could enhance the revenue growth rate beginning in 2027. Wells Fargo lowered its price target on IRTC to $150 from $168 following the deal, while maintaining an Overweight rating; separately, commentary referencing Q2 2026 results noted revenue up 20.1% and raised full-year guidance.
IRTC closed at $106.68, below both its 50-day average of $117.20 and 200-day average of $126.60, with the 50-day below the 200-day. Shares are down 4.3% over one month, 5.2% over three months, and 39.6% over one year, sitting near the 52-week low of $100.70. The GekkoIndex reads 64.5, placing the stock in the Accumulation zone, while price stands 13.9% below Gekko Fair Value of $123.86.
Earnings are scheduled for 29 October, 17 days away, falling within a typical 20-trading-day holding window, with the last report showing an EPS beat of -0.01 versus an estimate of -0.04 and a 2.7% reaction. No insider, Congress, or unusual options activity appears in their respective windows. Seasonally, the next 20 trading days have averaged 17.2% over 5 years, rising in 2 of them. Analyst consensus across 12 firms is unanimously Buy, with a consensus target of $173.93.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
iRhythm price vs fair value
Close $106.68200-day averageGekko Fair Value $123.86
iRhythm quick facts
- Market cap
- $3.51B
- P/E ratio
- —
- Forward P/E
- 90.9
- EPS, TTM
- −$0.42
- Revenue, TTM
- $825.3M
- Profit margin
- -1.7%
- Dividend yield
- —
- Beta
- 1.46
- Volume
- 384,396 avg 500,547
- 1-year return
- −39.6%
- Typical daily move
- ±3.7%
- Typical 20-day move
- ±9.1%
- 50-day average
- $117.20
- 200-day average
- $126.60
- Next earnings
- Oct 29 after close
- Shares outstanding
- 32.96M
iRhythm swing-trade checklist
iRhythm scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $106.68 is below the 50-day ($117.20) and 200-day ($126.60) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
64.5, Accumulation
Reading 64.5 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
13.9% below
Price is 13.9% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 17 days
Reports on Oct 29, 2026, 17 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+17.2% on average
From this point in the calendar, the next 20 trading days averaged +17.2% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
iRhythm stock chart and price history
iRhythm closed at $106.68 on Oct 12, 2026, −39.6% over the past year, inside a 52-week range of $100.70 to $212.00.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −4.3%
- 3 months
- −5.2%
- 6 months
- −11.4%
- 1 year
- −39.6%
The full IRTC chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open IRTC in Gekko
Follow iRhythm through every session
Put IRTC on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track IRTC in GekkoFree for 7 days. No credit card required.
About iRhythm
iRhythm makes wearable heart monitoring devices for patients in the United States who may be at risk of irregular heartbeats. Its main product, the Zio service, pairs a wireless, patch-style biosensor that patients wear on the skin with a cloud-based platform that analyzes the recorded data. The biosensors, available in versions such as Zio XT and AT, are disposable and capture heartbeat and ECG readings so that clinicians can monitor cardiac activity and identify arrhythmias.
The company works with Verily Life Sciences LLC on joint development work aimed at new methods for screening, detecting and monitoring atrial fibrillation. Its customers are medical professionals who rely on the Zio system's combination of hardware and data analysis to track patient heart health over time.
iRhythm was founded in 2006 and is headquartered in San Francisco, California. Its shares are listed on the NASDAQ under the ticker IRTC.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- irhythmtech.com
iRhythm GekkoIndex: the smart money zone
iRhythm’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 64.5, in the Accumulation zone, down 0.4 points over five sessions.
64.5Accumulation
Down 0.4 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 33 | +1.3% | +14.6% |
| Accumulation (current zone) | 256 | +0.9% | +2.3% |
| Neutral | 338 | −0.6% | −1.9% |
| Distribution | 43 | +0.3% | +1.9% |
| Selling | 12 | +3.0% | +0.8% |
Average IRTC share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the IRTC price, zone by zone.Track IRTC in Gekko
Is iRhythm stock overvalued? Gekko Fair Value
iRhythm trades 13.9% below Gekko Fair Value of $123.86, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what iRhythm shares are worth, recalculated every trading day.
$123.86
Gekko Fair Value, Oct 10, 2026
13.9% Undervalued
At the end of Aug 2026 the price was 7.0% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open IRTC in Gekko
iRhythm insider and Congress trading
No open-market insider purchases were filed for iRhythm, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in IRTC were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for IRTC, plotted on the chart in Gekko.Open IRTC in Gekko
Buybacks
iRhythm has been buying back its own shares.
- Bought back, quarter ended Mar 31, 2024
- $25.00M
- As a share of market cap
- 0.71%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
0of the funds Gekko tracks hold IRTC.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
iRhythm earnings: next date and track record
iRhythm reports on Oct 29, 2026, after the close (17 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Oct 29, 2026
Expected after the close, 17 days away
- EPS estimate
- $0.02
- Revenue estimate
- $222.3M
6 of 8reports beat the EPS estimate
±7.2%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- iRhythm reported Q2 2026 revenue of $224.2 million, up 20.1% year-over-year, marking seven consecutive quarters of 20%+ growth. Growth was driven by cardiology, primary care, innovative channels, and international markets, with notable margin expansion demonstrating operating leverage. The company announced an acquisition of VitalConnect, adding four cardiac monitoring modalities, FDA-cleared hospital monitoring capabilities, and multi-vital biosensor technology to expand their platform.
- Guidance
- Management expects the VitalConnect acquisition to strengthen long-term growth profile. Full financial guidance details were to be provided by CFO Dan Wilson, but transcript was cut off before specific revenue or earnings targets were disclosed.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.01 est −$0.04 | $224.2M est $219.3M | +2.7% |
| Apr 30, 2026 | −$0.43 est −$0.56 | $199.4M est $194.1M | 0.0% |
| Feb 19, 2026 | $0.17 est $0.02 | $208.9M est $201.9M | −1.9% |
| Oct 30, 2025 | −$0.06 est −$0.36 | $192.9M est $201.8M | +1.1% |
| Jul 31, 2025 | −$0.44 est −$0.53 | $186.7M est $174.0M | +17.8% |
| May 1, 2025 | −$0.95 est −$0.89 | $158.7M est $153.4M | +22.7% |
| Feb 20, 2025 | $0.01 est −$0.29 | $164.3M est $158.3M | +5.7% |
| Oct 30, 2024 | −$1.26 est −$0.55 | $147.5M est $157.3M | −5.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
iRhythm stock forecast and analyst price targets
Analysts’ average 12-month price target for iRhythm is $173.93, +63.0% from the last close, from 12 firms rating the stock in the last 90 days.
$173.93consensus 12-month target, +63.0% from the last close
Now $106.68Avg $173.93
Low $150High $196
Each firm’s latest rating in the last 90 days: 12 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 6 | Wells Fargo | $150 | +40.6% |
| Oct 5 | Canaccord Genuity | $196 | +83.7% |
| Oct 5 | Needham | $194 | +81.9% |
| Sep 24 | Wells Fargo | $168 | +57.5% |
| Sep 4 | William Blair | — | — |
+2.3%average 20-day move after past Accumulation readings
+17.2%average move over the next 20 trading days in the last 5 years
±3.7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
iRhythm seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, iRhythm averaged +17.2% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.3% | 3 of 5 |
| Next 10 trading days | +5.5% | 3 of 5 |
| Next 15 trading days | +8.8% | 4 of 5 |
| Next 20 trading days | +17.2% | 2 of 5 |
| Next 30 trading days | +10.7% | 3 of 5 |
For scale, IRTC’s typical 20-trading-day move in either direction is about 9.1%.
iRhythm market cap and key statistics
iRhythm’s market cap is $3.51B and revenue of $825.3M over the last twelve months.
Valuation
- Market cap
- $3.51B
- Forward P/E
- 90.9
- EPS, TTM
- −$0.42
- Gekko Fair Value
- $123.86
Trading
- Volume
- 384,396
- Avg volume, 20 days
- 500,547
- 52-week high
- $212.00
- 52-week low
- $100.70
- Shares outstanding
- 32.96M
Financials
- Revenue, TTM
- $825.3M
- Profit margin
- -1.7%
- Return on equity
- -9.6%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.46
- Typical daily move
- ±3.7%
- Typical 20-day move
- ±9.1%
iRhythm stock news this week
Coverage of iRhythm this week reads positive: 6 positive, 1 neutral and 2 negative headlines.
- iRhythm Holdings (IRTC) Disclosed Unauthorized Access To Patient DataYahoo Finance, Oct 9
- Analysts Offer Insights on Healthcare Companies: Option Care Health (OPCH) and Irhythm Technologies (IRTC)The Globe and Mail, Oct 7
- iRhythm Technologies (IRTC): Cyberattack Disclosure Turns Data Risk Into an Investor CatalystAlphaStreet, Oct 7
- iRhythm Holdings Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Patient Data Is ExposedGlobeNewsWire, Oct 6
- iRhythm completes acquisition of VitalConnectMassDevice, Oct 6
- iRhythm stock price target lowered to $150 by Wells Fargo on model updateInvesting.com, Oct 6
iRhythm peers
iRhythm’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 18.2% above |
| ABTAbbott Laboratories | Neutral | 14.7% below |
| DHRDanaher | Neutral | 4.5% above |
| ISRGIntuitive Surgical | Neutral | 18.8% above |
| MDTMedtronic | Neutral | 22.9% below |
| SYKStryker | Accumulation | 12.6% below |
A peer links to its own page where one exists.
iRhythm stock FAQ
What is iRhythm’s market cap?
iRhythm’s market cap is $3.51B at the Oct 12, 2026 close of $106.68, with 32.96M shares outstanding.
What is the iRhythm stock forecast?
The consensus analyst 12-month price target for iRhythm is $173.93, +63.0% from the last close. Of the 12 firms that rated the stock in the last 90 days, 12 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is iRhythm stock overvalued or undervalued?
On Gekko’s estimate iRhythm is undervalued: the Oct 12, 2026 close of $106.68 is 13.9% below Gekko Fair Value of $123.86. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does iRhythm report earnings next?
iRhythm is expected to report on Oct 29, 2026, after the market closes (17 days away). Analysts expect earnings of $0.02 per share on revenue of $222.3M. iRhythm beat the earnings estimate in 6 of its last 8 reports, moving 7.2% on average across the report.
What is iRhythm’s 52-week high and low?
iRhythm’s 52-week high is $212.00 and its 52-week low is $100.70; it closed at $106.68 on Oct 12, 2026, −39.6% over the past year.
Is iRhythm stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (gekkoindex and fair value), 1 as mixed (seasonality) and 2 as headwinds (trend and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See iRhythm the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.